ImmuPharma

ImmuPharma PLC, listed on London’s AIM and dual listed on Euronext Growth Brussels, is a specialty biopharmaceutical company focusing on developing new innovative peptide drugs for patients with serious medical conditions. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, anti-infectives, metabolic diseases and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulatory, which is in Phase III for the treatment of lupus, a potentially life threatening autoimmune disease.  Preclinical analysis suggest that Lupuzor™ as a platform technology, has therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new optimised International Phase III trial for Lupuzor™ in lupus and commercialise in the US.

 

e6P4njUWcW0CS72n.jpg

Dimitri F. Dimitriou MSc

CEO & Co-founder

 

Mr Dimitriou has 30 years’ experience in the pharmaceutical and biotech industry. He is a co-founder and CEO of ImmuPharma PLC. His past roles include Senior Director, Worldwide Business Development at GlaxoSmithKline, where his responsibilities included worldwide corporate deals with pharmaceutical and biotech companies. He held a similar role in Europe for Bristol-Myers Squibb. Prior to that, he spent 8 years at Procter & Gamble in senior marketing, R&D and business development positions and began his career in marketing at Novartis in 1987. He has 2 degrees from the University of London - a Bachelor’s in biochemistry from Kings College and a Master’s in pathology and toxicology from Imperial College Medical School.

 

K2Tnr46FshJHmAdn.jpg

Lisa Baderoon

Head of Investor Relations

 

Lisa Baderoon has spent over 20 years working within the City of London and has been involved with a diverse portfolio of clients from a variety of sectors but with a leaning towards emerging, high growth businesses advising both private and public companies on their media and investor relations strategies. During this time she has been involved in a multitude of client transactions spanning private fund raisings, Initial Public Offerings (IPO’s) and mergers and acquisitions both in the UK and internationally. Until December 2011 she was a Partner at Buchanan Communications, one of the leading City financial public relations agencies, where she was instrumental in establishing its successful healthcare franchise. Her client responsibilities included developing impactful IR strategies in addition to excellence in message development and managing relationships with media, the investment community and sell side analysts in Europe. She also has significant issue and crisis management experience from both an investor and media perspective.
Over the last eight years she has been advising ImmuPharma as a client on its media and investor relations strategy and in February 2012 was appointed Head of Investor Relations at the Company. Lisa has also recently founded Just B Communications Ltd, a consultancy which specialises in helping businesses develop effective communications and through her network of blue-chip London City contacts providing access to a number of sources of corporate and investor development opportunities.

 


Interessante links


Contactgegevens



ImmuPharma PLC
One Bartholomew Close
London
EC1A 7BL
Tel: +44 20 7152 4080
Fax: +44 20 7152 4001
investors@immupharma.com